促红细胞生成素产生肝细胞受体在肝纤维化、肝癌发病机制中的作用

童伟钊; 刘伟; 胡国信

doi:10.3969/j.issn.1001-5256.2021.11.038

促红细胞生成素产生肝细胞受体在肝纤维化、肝癌发病机制中的作用

DOI: 10.3969/j.issn.1001-5256.2021.11.038

童伟钊^{1, 2},
刘伟³,
胡国信^1, ,

1.
北京大学深圳医院感染性疾病科，广东深圳 518036
2.
汕头大学医学院，广东汕头 515041
3.
深圳北京大学香港科技大学医学中心生物医学研究所，深圳市神经结构生物学重点实验室，广东深圳 518036

基金项目:

国家自然科学基金 (81473473)

详细信息

通信作者:
胡国信，huguoxin8228@sina.com

中图分类号: R575.2;R735.7
计量
- 文章访问数: 496
- HTML全文浏览量: 309
- PDF下载量: 37
- 被引次数: 0
出版历程
- 收稿日期: 2021-07-30
- 录用日期: 2021-08-31
- 出版日期: 2021-11-20

Role of erythropoietin-producing hepatocyte receptors in the pathogenesis of liver fibrosis and hepatocellular carcinoma

Weizhao TONG^{1, 2},
wei LIU³,
Guoxin HU^{1
, ,}

1.
Department of Infectious Diseases, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, China
2.
Shantou University Medical College, Shantou, Guangdong 515041, China
3.
Biomedical Research Institute, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center; Shenzhen Key Laboratory for Neuronal Structural Biology, Shenzhen 518036, China

Research funding:

National Natural Science Foundation of China (81473473)

摘要

摘要: 促红细胞生成素产生肝细胞(Eph)受体是受体酪氨酸激酶家族中最大的亚族，参与机体胚胎发育、血管生成、轴突导向等生理过程。近来有研究显示，Eph受体过量表达于肝纤维化及肝癌组织中，并在肝癌的生长、侵袭、转移中发挥重要作用。探讨了Eph受体在肝纤维化及肝细胞癌中的作用机制，提示Eph受体可能是肝纤维化、肝癌发生发展过程中的重要分子。
- 促红细胞产生肝细胞受体 /
- 肝硬化 /
- 癌, 肝细胞
Abstract: Erythropoietin-producing hepatocyte (Eph) receptors are the largest subgroup of the receptor tyrosine kinase family and are involved in the physiological processes such as embryonic development, angiogenesis, and axon guidance. Recent studies have shown that Eph receptors are overexpressed in liver fibrosis and hepatocellular carcinoma tissues and play an important role in the growth, invasion, and metastasis of hepatocellular carcinoma. This article explores the mechanism of action of Eph receptors in liver fibrosis and hepatocellular carcinoma and points out that Eph receptors may be important molecules in the development and progression of liver fibrosis and hepatocellular carcinoma.
- Erythropoietin Producing Hepatocyte Receptor /
- Liver Cirrhosis /
- Carcinoma, Hepatocellular

HTML全文

图 1 Eph/Ephrin结构特点及双向信号通路

下载: 全尺寸图片幻灯片

图 2 Eph受体在肝纤维化、HCC中的作用机制

下载: 全尺寸图片幻灯片

参考文献(38)

[1]	KANDA T, GOTO T, HIROTSU Y, et al. Molecular mechanisms driving progression of liver cirrhosis towards hepatocellular carcinoma in chronic hepatitis B and C infections: A review[J]. Int J Mol Sci, 2019, 20(6): 1358. DOI: 10.3390/ijms20061358.
[2]	WANG YC, DAI Y, XU GL, et al. Association between EphA1 and tumor microenvironment in gastric carcinoma and its clinical significance[J]. Med Sci Monit, 2020, 26: e923409. DOI: 10.12659/MSM.923409.
[3]	LI JY, XIAO T, YI HM, et al. S897 phosphorylation of EphA2 is indispensable for EphA2-dependent nasopharyngeal carcinoma cell invasion, metastasis and stem properties[J]. Cancer Lett, 2019, 444: 162-174. DOI: 10.1016/j.canlet.2018.12.011.
[4]	WANG L, PENG Q, SAI B, et al. Ligand-independent EphB1 signaling mediates TGF-β-activated CDH2 and promotes lung cancer cell invasion and migration[J]. J Cancer, 2020, 11(14): 4123-4131. DOI: 10.7150/jca.44576.
[5]	WANG Y, YU H, SHAN Y, et al. EphA1 activation promotes the homing of endothelial progenitor cells to hepatocellular carcinoma for tumor neovascularization through the SDF-1/CXCR4 signaling pathway[J]. J Exp Clin Cancer Res, 2016, 35: 65. DOI: 10.1186/s13046-016-0339-6.
[6]	ANDERTON M, van der MEULEN E, BLUMENTHAL MJ, et al. The role of the Eph receptor family in tumorigenesis[J]. Cancers (Basel), 2021, 13(2): 206. DOI: 10.3390/cancers13020206.
[7]	ZHANG XH, MA N, LYU CY, et al. Role of receptor tyrosine kinase Eph in hepatocellular carcinoma[J]. Chin J Surg Oncol, 2019, 11(2): 136. DOI: 10.3969/j.issn.1674-4136.2019.02.014. 张晓华, 马宁, 吕成余, 等. 受体酪氨酸激酶Eph受体在肝细胞癌中作用的研究进展[J]. 中国肿瘤外科杂志, 2019, 11(2): 136. DOI: 10.3969/j.issn.1674-4136.2019.02.014.
[8]	HIRAI H, MARU Y, HAGIWARA K, et al. A novel putative tyrosine kinase receptor encoded by the eph gene[J]. Science, 1987, 238(4834): 1717-1720. DOI: 10.1126/science.2825356.
[9]	LIANG LY, PATEL O, JANES PW, et al. Eph receptor signalling: From catalytic to non-catalytic functions[J]. Oncogene, 2019, 38(39): 6567-6584. DOI: 10.1038/s41388-019-0931-2.
[10]	Unified nomenclature for Eph family receptors and their ligands, the ephrins. Eph Nomenclature Committee[J]. Cell, 1997, 90(3): 403-404. DOI: 10.1016/s0092-8674(00)80500-0.
[11]	PASQUALE EB. Eph receptor signalling casts a wide net on cell behaviour[J]. Nat Rev Mol Cell Biol, 2005, 6(6): 462-475. DOI: 10.1038/nrm1662.
[12]	PASQUALE EB. Eph receptors and ephrins in cancer: Bidirectional signalling and beyond[J]. Nat Rev Cancer, 2010, 10(3): 165-180. DOI: 10.1038/nrc2806.
[13]	BATLLE E, WILKINSON DG. Molecular mechanisms of cell segregation and boundary formation in development and tumorigenesis[J]. Cold Spring Harb Perspect Biol, 2012, 4(1): a008227. DOI: 10.1101/cshperspect.a008227.
[14]	GONG J, KÖRNER R, GAITANOS L, et al. Exosomes mediate cell contact-independent ephrin-Eph signaling during axon guidance[J]. J Cell Biol, 2016, 214(1): 35-44. DOI: 10.1083/jcb.201601085.
[15]	FALIVELLI G, LISABETH EM, RUBIO de la TORRE E, et al. Attenuation of eph receptor kinase activation in cancer cells by coexpressed ephrin ligands[J]. PLoS One, 2013, 8(11): e81445. DOI: 10.1371/journal.pone.0081445.
[16]	GOPAL U, BOHONOWYCH JE, LEMA-TOME C, et al. A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion[J]. PLoS One, 2011, 6(3): e17649. DOI: 10.1371/journal.pone.0017649.
[17]	LARSEN AB, STOCKHAUSEN MT, POULSEN HS. Cell adhesion and EGFR activation regulate EphA2 expression in cancer[J]. Cell Signal, 2010, 22(4): 636-644. DOI: 10.1016/j.cellsig.2009.11.018.
[18]	WU B, ROCKEL JS, LAGARES D, et al. Ephrins and eph receptor signaling in tissue repair and fibrosis[J]. Curr Rheumatol Rep, 2019, 21(6): 23. DOI: 10.1007/s11926-019-0825-x.
[19]	IEGUCHI K, MARU Y. Roles of EphA1/A2 and ephrin-A1 in cancer[J]. Cancer Sci, 2019, 110(3): 841-848. DOI: 10.1111/cas.13942.
[20]	DUSABLON A, PARKS J, WHITEHURST K, et al. EphrinA1-Fc attenuates myocardial ischemia/reperfusion injury in mice[J]. PLoS One, 2017, 12(12): e0189307. DOI: 10.1371/journal.pone.0189307.
[21]	WIJERATNE D, RODGER J, STEVENSON A, et al. Ephrin-A2 affects wound healing and scarring in a murine model of excisional injury[J]. Burns, 2019, 45(3): 682-690. DOI: 10.1016/j.burns.2018.10.002.
[22]	LI Y, YAN H, WANG F, et al. Activation of EphA1-Epha receptor axis attenuates diabetic nephropathy in mice[J]. Biochem Biophys Res Commun, 2017, 486(3): 693-699. DOI: 10.1016/j.bbrc.2017.03.100.
[23]	LAGARES D, GHASSEMI-KAKROODI P, TREMBLAY C, et al. ADAM10-mediated ephrin-B2 shedding promotes myofibroblast activation and organ fibrosis[J]. Nat Med, 2017, 23(12): 1405-1415. DOI: 10.1038/nm.4419.
[24]	MIMCHE PN, BRADY LM, BRAY CF, et al. The receptor tyrosine kinase EphB2 promotes hepatic fibrosis in mice[J]. Hepatology, 2015, 62(3): 900-914. DOI: 10.1002/hep.27792.
[25]	MIMCHE PN, LEE CM, MIMCHE SM, et al. EphB2 receptor tyrosine kinase promotes hepatic fibrogenesis in mice via activation of hepatic stellate cells[J]. Sci Rep, 2018, 8(1): 2532. DOI: 10.1038/s41598-018-20926-9.
[26]	CHEN X, ZHANG D, WANG Y, et al. Synergistic antifibrotic effects of miR-451 with miR-185 partly by co-targeting EphB2 on hepatic stellate cells[J]. Cell Death Dis, 2020, 11(5): 402. DOI: 10.1038/s41419-020-2613-y.
[27]	IIDA H, HONDA M, KAWAI HF, et al. Ephrin-A1 expression contributes to the malignant characteristics of {alpha}-fetoprotein producing hepatocellular carcinoma[J]. Gut, 2005, 54(6): 843-851. DOI: 10.1136/gut.2004.049486.
[28]	FAN M, LIU Y, XIA F, et al. Increased expression of EphA2 and E-N cadherin switch in primary hepatocellular carcinoma[J]. Tumori, 2013, 99(6): 689-696. DOI: 10.1700/1390.15457.
[29]	YIN JP, YUE ZC, ZHUO SY. STAT3: A key molecule in the progression of liver cancer mediated by chronic inflammation[J]. J Clin Hepatol, 2020, 36(4): 948-952. DOI: 10.3969/j.issn.1001-5256.2020.04.054. 音金萍, 岳紫晨, 卓少元. STAT3: 慢性炎症介导肝癌进程的关键分子[J]. 临床肝胆病杂志, 2020, 36(4): 948-952. DOI: 10.3969/j.issn.1001-5256.2020.04.054.
[30]	WANG H, HOU W, PERERA A, et al. Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling[J]. Cell Rep, 2021, 34(8): 108765. DOI: 10.1016/j.celrep.2021.108765.
[31]	LV XY, WANG J, HUANG F, et al. EphA3 contributes to tumor growth and angiogenesis in human gastric cancer cells[J]. Oncol Rep, 2018, 40(4): 2408-2416. DOI: 10.3892/or.2018.6586.
[32]	WANG W, JIA WD, HU B, et al. RAB10 overexpression promotes tumor growth and indicates poor prognosis of hepatocellular carcinoma[J]. Oncotarget, 2017, 8(16): 26434-26447. DOI: 10.18632/oncotarget.15507.
[33]	LU CY, YANG ZX, ZHOU L, et al. High levels of EphA3 expression are associated with high invasive capacity and poor overall survival in hepatocellular carcinoma[J]. Oncol Rep, 2013, 30(5): 2179-2186. DOI: 10.3892/or.2013.2679.
[34]	YAN Y, LUO YC, WAN HY, et al. MicroRNA-10a is involved in the metastatic process by regulating Eph tyrosine kinase receptor A4-mediated epithelial-mesenchymal transition and adhesion in hepatoma cells[J]. Hepatology, 2013, 57(2): 667-677. DOI: 10.1002/hep.26071.
[35]	CHEN G, WANG Y, ZHOU M, et al. EphA1 receptor silencing by small interfering RNA has antiangiogenic and antitumor efficacy in hepatocellular carcinoma[J]. Oncol Rep, 2010, 23(2): 563-570.
[36]	MIAO H, LI DQ, MUKHERJEE A, et al. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt[J]. Cancer Cell, 2009, 16(1): 9-20. DOI: 10.1016/j.ccr.2009.04.009.
[37]	ZANTEK ND, AZIMI M, FEDOR-CHAIKEN M, et al. E-cadherin regulates the function of the EphA2 receptor tyrosine kinase[J]. Cell Growth Differ, 1999, 10(9): 629-638.
[38]	LI N, SHI K, LI W. TUSC7: A novel tumor suppressor long non-coding RNA in human cancers[J]. J Cell Physiol, 2018, 233(9): 6401-6407. DOI: 10.1002/jcp.26544.